Lung Carcinoma — Research

Lung Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	273,384	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	94,693	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	19,676	`("Lung Carcinoma"[tiab] OR "Lung Cancer"[tiab] OR "Carcinoma of Lung"[tiab] OR "Carcinoma of the Lung"[tiab] OR "Lung Cancer all types"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (381)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 326–350 of 381 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
· Proc Natl Acad Sci U S A · 2015 · PMID 25733882 · validated civic_curation pubmed
LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.
· Acta Pharmacol Sin · 2015 · PMID 26027660 · validated civic_curation pubmed
Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.
· Cancer Res · 2009 · PMID 19366796 · validated civic_curation pubmed
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.